Avid Bioservices, Inc.

NasdaqCM:CDMO Stock Report

Market Cap: US$786.7m

Avid Bioservices Past Earnings Performance

Past criteria checks 0/6

Avid Bioservices's earnings have been declining at an average annual rate of -33.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 17.7% per year.

Key information

-33.1%

Earnings growth rate

-31.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate17.7%
Return on equity-339.3%
Net Margin-101.1%
Last Earnings Update31 Oct 2024

Recent past performance updates

Recent updates

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Aug 26
Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Jul 29
Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Mar 07
There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Feb 28
We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Dec 28
There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Nov 10
Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Oct 15
Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Jun 23
Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Jun 12
Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

May 21
Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

May 12
Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Mar 13
Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden

Nov 10
Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden

Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M

Sep 06

Revenue & Expenses Breakdown

How Avid Bioservices makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CDMO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Oct 24150-152320
31 Jul 24142-144280
30 Apr 24140-141260
31 Jan 24137-18270
31 Oct 23141-12270
31 Jul 23150-3280
30 Apr 231490280
31 Jan 23141116260
31 Oct 22134119250
31 Jul 22126123230
30 Apr 22120128210
31 Jan 2211610200
31 Oct 211069190
31 Jul 211016180
30 Apr 21963170
31 Jan 21810160
31 Oct 2073-5150
31 Jul 2070-7140
30 Apr 2060-15150
31 Jan 2064-10150
31 Oct 1964-9150
31 Jul 1956-11140
30 Apr 1954-10130
31 Jan 1943-16130
31 Oct 1837-24150
31 Jul 1839-30160
30 Apr 1854-25160
31 Jan 1865-17180
31 Oct 1769617-16
31 Jul 17791118-9
30 Apr 1758-3180
31 Jan 1759-171816
31 Oct 1654-481947
31 Jul 1641-571954
30 Apr 1644-1180
31 Jan 1635-601955
31 Oct 1534-561951
31 Jul 1531-551947
30 Apr 1527-541943
31 Jan 1524-511840
31 Oct 1422-471836
31 Jul 1423-421833
30 Apr 1422-361728
31 Jan 1420-341725

Quality Earnings: CDMO is currently unprofitable.

Growing Profit Margin: CDMO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CDMO is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.

Accelerating Growth: Unable to compare CDMO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CDMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: CDMO has a negative Return on Equity (-339.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:20
End of Day Share Price 2024/12/23 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avid Bioservices, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew HewittCraig-Hallum Capital Group LLC
Vernon BernardinoFBR Capital Markets & Co.
Joseph PantginisH.C. Wainwright & Co.